LGLiliana Groppa

Liliana Groppa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Liliana Groppa has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Calprotectin – clinical and diagnostic value in rheumatoid arthritis

    by Vlada Zanosiev, Eugen Russu, Oxana Bujor, Liliana Groppa

    Introduction. Rheumatoid arthritis is a systemic autoimmune disease in which persistent synovitis drives joint destruction and disability. Conventional biomarkers such as C-reactive protein and erythrocyte sedimentation rate are widely used to assess disease activity, but they fail to capture inflammation in a considerable proportion of patients and may be confounded by therapies such as interleukin-6 inhibition. Calprotectin (S100A8/A9, MRP8/14), a neutrophil- and monocytederived alarmin, has emerged as a potential biomarker reflecting the true inflammatory burden in rheumatoid arthritis. This review aimed to critically appraise the clinical and diagnostic value of calprotectin in adult rheumatoid arthritis, with emphasis on its relationship to disease activity, comparative performance against C-reactive protein and erythrocyte sedimentation rate, methodological aspects of measurement, and role in therapeutic monitoring. Material and methods. We systematically reviewed studies published between 2010 and 2025 that investigated calprotectin in adult rheumatoid arthritis, focusing on serum, plasma, synovial fluid, and fecal measurements, and their associations with disease activity, imaging, treatment response, and outcomes. Additionally, seminal articles published before 2010 were included when they provided essential historical context or foundational theoretical data relevant to the understanding of calprotectin in rheumatoid arthritis. Pediatric and animal studies were excluded. Results. Serum calprotectin is consistently elevated in rheumatoid arthritis compared with healthy controls and correlates strongly with swollen joint counts, composite indices, and ultrasound-detected synovitis, often outperforming C-reactive protein and erythrocyte sedimentation rate. Synovial fluid calprotectin is markedly increased, reflecting local production and aggressive synovitis, while fecal calprotectin has limited utility except in cases of concomitant gastrointestinal involvement. Importantly, calprotectin levels remain reliable in patients receiving IL-6 inhibitors, where C-reactive protein is suppressed. High baseline calprotectin predicts radiographic progression and poor functional outcomes, whereas declining levels parallel therapeutic response to DMARDs and biologics. Recent studies suggest calprotectin may help identify patients at risk of relapse during apparent remission, though its predictive value for treatment response to TNF inhibitors appears limited. Conclusions. Calprotectin is a sensitive biomarker of inflammation in rheumatoid arthritis, offering distinct advantages over traditional acute-phase reactants in detecting residual disease and guiding therapeutic monitoring. Standardisation of assays, establishment of validated cut-off values, and large prospective validation studies are required before routine integration into clinical practice.

  • Open Access

    Impact of COVID-19 on chronic kidney disease progression: a prospective cohort study

    by Tatiana Răzlog, Eugeniu Russu, Costina Groza, Liliana Groppa

    Introduction. Chronic kidney disease and COVID-19 are both associated with significant morbidity. Patients with chronic kidney disease are at risk for severe COVID-19, and SARS-CoV-2 infection may accelerate CKD progression. This study aimed to compare renal outcomes in CKD patients with and without prior COVID-19 and to identify predictors of progression. Materials and methods. We conducted a prospective cohort study of 280 pre-dialysis CKD patients (stages G2-G5), followed for 12 months. Of these, 140 had a history of COVID-19 (post-COVID group), and 140 had no such history (control group). Baseline assessments included renal function (eGFR, creatinine, urea), inflammatory markers (CRP, ferritin, LDH), hematologic indices (hemoglobin, leukocytes, platelets), and SF-36 quality of life scores. CKD progression was defined as a ≥30% eGFR decline or the initiation of dialysis. Analyses included group comparisons, correlations, logistic regression, and ROC curves. Results. Baseline characteristics and mean eGFR (~60 mL/min/1.73 m²) were similar across groups. CRP and ferritin levels were elevated in both groups without significant differences. Post-COVID patients reported lower vitality and higher social functioning on SF-36 (both p ≤ 0.001). After 12 months, the post-COVID group showed greater eGFR decline (-3.1 vs -1.2 mL/min) and a higher progression rate (28% vs 15%, p ≤ 0.01). Multivariable analysis identified prior COVID-19 (adjusted OR ≈2.3, 95% CI: 1.3-4.0) and low baseline hemoglobin as independent predictors of progression; CRP and ferritin were not predictive. LDH showed a modest association. Hemoglobin alone predicted progression with an AUC of 0.78; the combined model (COVID status + hemoglobin) yielded an AUC of 0.85. Conclusions. CKD patients with prior COVID-19 experienced a faster renal function decline over one year than those without COVID-19. Persistent anemia and elevated LDH were also associated with increased progression risk. These findings emphasize the importance of post-COVID renal monitoring and early intervention in CKD patients to prevent deterioration.

  • Open Access

    Carotid Atherosclerosis and T-Cell Imbalance in Women with Rheumatoid Arthritis: A Cross-Sectional Study of Intima–Media Thickness, Anti-CCP Antibodies and CD4/CD8 Ratio

    by Elena Deseatnicova, Alesea Nistor, Ana Tigulea, Maia Grosu, Stela Dodu, Eugeniu Russu, Lucia Andries, Liliana Groppa

    Background: Rheumatoid arthritis (RA) is associated with increased cardiovascular risk beyond traditional risk factors. Carotid intima–media thickness (IMT) is a marker of subclinical atherosclerosis and may be influenced by chronic inflammation in RA. Objectives: This study aimed to compare carotid IMT between women with RA and age-matched controls, and to investigate the associations between IMT and RA-related factors, including disease duration, menopausal status, anti-cyclic citrullinated peptide (anti-CCP) antibodies and the CD4/CD8 T-cell ratio. Methods: This cross-sectional study included 59 women with RA and 55 age-matched controls. All RA patients received methotrexate and had no recent biologic DMARD exposure. Carotid IMT was measured by B-mode ultrasonography. Clinical, laboratory, and immunologic parameters, including anti-CCP antibodies and CD4/CD8 ratio, were analyzed. Results: Mean carotid IMT was significantly higher in RA patients than in controls (0.85 ± 0.09 vs. 0.63 ± 0.08 mm, p < 0.0001). Within the RA group, IMT correlated positively with disease duration (r = 0.48, p < 0.001), years since menopause (ρ = 0.44, p = 0.001), anti-CCP titers (r = 0.31, p = 0.018) and CD4/CD8 ratio (r = 0.42, p < 0.001), and inversely with CD8 T-cell counts (r = −0.34, p = 0.009). In multivariable analysis, RA duration and CD4/CD8 ratio remained independently associated with IMT after adjustment for age, lipids and blood pressure. Conclusions: Women with RA had greater carotid IMT than age-matched controls. Longer disease duration and a higher CD4/CD8 ratio were independently associated with IMT, supporting a link between cumulative disease burden, T-cell imbalance and subclinical carotid atherosclerosis in RA. These findings support routine cardiovascular risk assessment and consideration of vascular imaging in high-risk RA subgroups.


  • Open Access

    Correlation between pathogenetic factors and vascular endothelial damage in patients with rheumatoid arthritis

    by Eugen Russu, Liliana Groppa, Lia Chislari, Svetlana Agachi, Marius Semionov, Chiril Nartea, Iosif Leanca, Artemie Pastuhov

    Introduction. Systemic rheumatoid vasculitis accounts for 1 to 5% of complications seen in rheumatoid arthritis, while autopsy studies report an average of 23% incidence. This enormous difference in numbers emphasizes the rate of misdiagnosis or underdiagnosis of systemic rheumatoid vasculitis. It mainly affects people with a median age of 65 years. It is particularly noteworthy, as systemic rheumatoid vasculitis has a high mortality and relapse rate. Also, the multifactorial aetiology: cytokines/immune cells and other particles determines clinical complexity of this type of angiitis. Materials and methods. A comprehensive literature search of articles published since 1996 was conducted using MEDLINE via PubMed and HINARI. The search included terms such as "rheumatoid vasculitis", "rheumatoid arthritis", and "endothelial dysfunction", focusing on mechanisms driving vascular damage. A total of 217 relevant sources were identified, including original studies, reviews, and book chapters. The study evaluated pathogenic factors like cytokines, immune complexes, and systemic inflammation, highlighting their roles in endothelial dysfunction and hypercoagulability. Results. The main pathogenetic factors in systemic rheumatoid vasculitis were immune complexes, cytokines (IL-6/TNF-α and IL-17), immune and blood cells (CD20/TH17/Platelets) and others (microparticles, blood rheology modifications). Even though, taken separately, those factors appear to have little to no impact on vascular endothelium, their synergistic effect lead to significant endothelial damage. Conclusions. To conclude, each disease has its own pathogenetic factors which determine the natural course of this pathology. Understanding these mechanisms plays an important role for clinicians helping them to diagnose and effective treatment. Taking into consideration the relationships between specific factors in rheumatoid angiitis, we can make more specific decisions for its diagnosis and treatment. We can also use the pathophysiology of systemic rheumatoid vasculitis as a foundation for developing prevention measures.

  • Open Access

    Rheumatoid arthritis worldwide: inequalities in epidemiology and care

    by Elena Deseatnicova, Valeria Frunze, Rodica Usatii, Liliana Groppa

    Introduction. Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 0.5% of the global population. It represents a major cause of disability, reduced quality of life, and healthcare burden. The prevalence of RA is rising, especially in older populations and in low-income regions. Materials and methods. A systematic literature search was performed in PubMed, ScienceDirect and Google Scholar for articles published between 2000 and 2025. Search terms included "rheumatoid arthritis", "epidemiology", "risk factors", "economic burden", and "healthcare disparities". Results. RA prevalence ranges from 0.3% to 1.0%, with the highest values in Northern Europe (0.8 - 1.0%) and North America (0.7 - 0.9%), and the lowest in Africa (0.1 - 0.3%) and rural Asia (0.2 - 0.4%). Work incapacity has declined in several high-income countries, attributed to earlier diagnosis and the widespread use of disease-modifying antirheumatic drugs. Socio-economic status is a key factor for RA outcomes, with patients in the lowest income groups showing up to 50% higher disability rates. Other risk factors include female sex, HLA-DRB1 alleles, smoking, and environmental exposures. The economic burden is considerable, with direct and indirect costs disproportionately affecting low- and middle-income countries, where RA frequently results in early work disability. Conclusions. RA causes disability and reduces quality of life. Its prevalence is rising worldwide, with higher detection and better outcomes in high-income countries, while low-income countries face underdiagnosis and limited access to modern therapies. Reducing these disparities requires stronger healthcare systems, early diagnosis, and affordable and accessible treatments.

  • Open Access

    Impact of Nutritional Diet Therapy on Rheumatoid Arthritis Disease Activity

    by Elena Deseatnicova, Eugenia Covaliov, Olga Deseatnicova, Rodica Siminiuc, Elena Rezus, Liliana Groppa

    Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial joint inflammation and different system involvement that results in considerable physical and psychological symptoms. This narrative review investigates the impacts of nutritional diet therapy on RA symptoms, highlighting recent scientific findings in terms of how different dietary components may modulate inflammation and disease activity. Treatment of RA includes conventional and biological disease-modifying antirheumatic drugs (DMARDs) and symptomatic response modifiers, like corticosteroids and non-steroidal antirheumatic drugs (NSAIDS). However, nutritional interventions are becoming more and more popular due to their ability to alter inflammation. The review also focuses on macronutrients such as proteins and fats, stressing the usefulness of omega-3 fat acids/monounsaturated fat acids but warning against high intake of processed carbohydrates/sugars. Besides that, it explores the effects of micronutrients and bioactive compounds like polyphenols which may minimize RA symptoms and result in better disease control together with vitamin D or probiotics. This study highlights that incorporating anti-inflammatory foods can benefit the health and well-being of RA patients. Dietary modification may serve as a supportive approach alongside conventional treatments, helping patients improve both physical and mental aspects of their condition and achieve a better quality of life.


  • Open Access

    Clinical and immunological assessment of thyroid pathology in rheumatoid arthritis

    by Elena Deseatnicova, Eugeniu Russu, Alexandru Corlateanu, Luana Andrea Macovei, Nistor Alesea, Lucia Andries, Elena Rezus, Liliana Groppa

     Introduction : Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by joint inflammation and significant extra-articular comorbidities. The autoimmune thyroid disease (AITD) is among the most frequent endocrine disorders associated with RA, reflecting potential shared immunopathogenic mechanisms. Aim : To evaluate the prevalence and clinical characteristics of thyroid dysfunction and autoimmunity in female patients with RA in comparison with a matched cohort of healthy controls and assess their association with disease activity and anti-cyclic citrullinated peptide antibodies (ACPA) positivity. Materials and methods : A cohort of 139 female RA patients was compared to 97 healthy controls. Thyroid function (TSH, fT4) and thyroid-specific antibodies (TPOAb, TgAb) were measured. RA disease activity was assessed using DAS28-ESR, with statistical analyses examining associations between thyroid pathology and RA features. Results : The prevalence of thyroid dysfunction among RA patients was 40.2%, which was significantly higher than the 8.24% observed in controls ( p r =0.6375). Moreover, higher RA disease activity correlated with an increased prevalence of thyroid pathology. Conclusion : Thyroid dysfunction and autoantibody positivity are significantly more prevalent in RA patients, suggesting shared autoimmune mechanisms. Routine thyroid function and antibody screening in RA management may facilitate early detection and improve outcomes.

  • Open Access

    Evaluarea dismicrobismului intestinal la pacienții cu sclerodermie sistemică: dezechilibre între flora patogenă și bacteriile comensale

    by Maria Lungu, Svetlana Agachi, Liliana Groppa, Oxana Bujor, Rodica Usatîi, Lilia Taran

    Systemic scleroderma (SS) is a rare autoimmune disease characterized by cutaneous and visceral fibrosis, vascular and immunological involvement. In recent years, the intestinal dysmicrobism has been recognized as an important factor in regulating the immune response and in the development of chronic inflammation. Intestinal dysmicrobism defined as the imbalance between commensal and pathogenic bacteria, has been associated with the severity and activity of the disease in SS. To evaluate the intestinal microbiota profile in patients with systemic scleroderma and to analyze the relationship between the microbiota imbalance and gastrointestinal clinical manifestations. The study included 74 patients with SS (70 women, 4 men, mean age 57.74 ± 1.05 years), hospitalized in 2024-2025 in rheumatology departments in the Republic of Moldova. The limited form was present in 64.86%, and the diffuse form in 35.14%. The status of the intestinal microbiota was assessed bacteriologically from intestinal content samples. Patients with SS showed a significant reduction in commensal bacteria (especially Lactobacillus species, Bifidobacterium spp.) and an increase in opportunistic and pro-inflammatory species (Escherichia coli, Candida spp., Klebsilla pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, Citrobacter freundi, Enterobacter cloacae). Dysmicrobism was identified in 85.14% of patients and correlated with the severity of digestive symptoms, especially dysphagia and heartburn. Intestinal dysmicrobism is common (85.14%) in SS and reflects an imbalance between protective and pathogenic flora. These changes may contribute to systemic inflammation and digestive dysfunction, highlighting the importance of evaluating the microbiota as a diagnostic and therapeutic tool.

  • Open Access

    Impact of urogenital and enterocolitic infections on the onset and evolution of ankylosing spondylitis and psoriatic arthritis

    by Chișlari Lia, Liliana Groppa, Alexandru Corlateanu, Eugeniu Russu

    Introduction : Infections such as Chlamydia trachomatis and Yersinia enterocolitica are recognized triggers of reactive arthritis, but their role in chronic spondyloarthritis (SpA)—including ankylosing spondylitis (AS) and psoriatic arthritis (PsA)—remains incompletely defined. Aim : To evaluate the potential role of selected urogenital and enterocolitic infections in the onset and clinical evolution of AS and PsA. Materials and methods : This prospective observational study included 1202 patients (709 PsA, 493 AS) followed between 2019 and 2025. Clinical subtypes, disease activity, and imaging features were assessed alongside multiplex PCR and serological screening for C. trachomatis , Mycoplasma spp., Ureaplasma spp., and Y. enterocolitica . Comparisons were made between infection-triggered and idiopathic cases. Results : Infection was found in 6.2% of PsA and 8.1% of AS patients, which was slightly higher than the control group. Infection-triggered cases presented more often with acute onset, oligoarthritis, and peripheral joint involvement (notably in AS, p =0.002). Over time, PsA showed a shift from oligoarticular to polyarticular and axial forms; axial PsA increased from 2.1% to 21.1% in 2 years. Radiographic and treatment outcomes were comparable between groups. A minority of infection-triggered cases showed remission following antibiotic therapy. Conclusions : Urogenital and enterocolitic infections may precipitate SpA in a small subset of genetically susceptible individuals, particularly with HLA-B27. While long-term disease trajectories resemble idiopathic forms, early identification of infectious triggers may aid in personalized management strategies. Further research is needed to clarify their role in chronic disease propagation and treatment responsiveness.